The efficacy of Navitoclax has been reported for the in vivo treatment of BRAFV600E melanoma models in combination with copper chelators, able to sequester copper required for MEK1 and MEK2 activity through a direct copper–MEK1/2 interaction [131]. This evidence concerns the gene MAP2K1 and melanoma.